Investigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLD

Listen as Marlyn J. Mayo, MD, discusses exciting new data from AASLD 2023 for people with PBC, including a late-breaking study of a dual PPAR agonist, biochemical response rates in people treated with an FXR agonist with or without a fibrate as second-line therapy, and evaluation of hyperlipidemia, atherosclerosis, and hepatic steatosis in people with PBC.